港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

藥明合聯

57.100

0.000

成交量：266.25萬

成交額：1.53億

市值：718.32億

市盈率：45.03

高：58.500

開：57.800

低：56.600

收：57.100

52周最高：85.500

52周最低：24.700

股本：12.58億

香港流通股本：12.58億

量比：0.97

換手率：0.21%

股息：- -

股息率：- -

每股收益(LYR):1.268

淨資產收益率：17.05%

總資產收益率：8.60%

市淨率：5.91

市盈率(LYR):45.03

市銷率: 10.67

資料載入中...

總覽公司新聞資訊公告

【券商聚焦】交銀國際維持藥明合聯(02268)買入評級指其今年有望迎來M端生產項目的大爆發

《大行》里昂：藥明合聯(02268.HK)提高盈利可見性目標價升至80.9元

阿斯达克财经

《大行》高盛微降藥明合聯(02268.HK)目標價至85.9元今年指引符合預期

阿斯达克财经

中金：維持藥明合聯(02268)跑贏行業評級目標價88.0港元

從「賦能者」到「定義者」，CRDMO行業龍頭藥明合聯(02268)的持續進化與價值躍遷

《大行》大摩予藥明合聯(02268.HK)評級「增持」目標價86元

阿斯达克财经

觸底反彈！華寶基金港股通創新藥ETF、港股通醫療ETF攜手衝高3%！業績超預期，藥明合聯、藥明康德強勢領升

《大行》瑞銀下調藥明合聯(02268.HK)目標價至90.4元產能擴張進度良好

阿斯达克财经

港股異動 | 創新藥概念股走高，藥明合聯升逾8%

老虎资讯综合

異動解讀 | 業績超預期！藥明合聯盤中大漲5.22%

【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質

藥明合聯2025年業績表現卓越，鞏固其在生物偶聯藥物CRDMO領域的全球領導地位

藥明合聯(02268)2025年業績高增延續，「全球擴張+技術賦能」牢築行業龍頭地位

藥明合聯(02268)2025年收益淨利雙增長公司擁有人應占經調整純利約15.59億元按年增長69.9%

智通财经网

【券商聚焦】交銀國際：CXO行情持續回暖料板塊估值倍數合理

港股異動 | 東曜藥業-B(01875)再升逾11% 年內股價已翻倍藥明合聯收購要約正式生效

【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新

港股異動 | 東曜藥業-B(01875)升逾9% 藥明合聯已取得公司60%股權有效接納收購要約正式生效

港股異動 | 東曜藥業-B(01875)午後升逾5% 藥明合聯收購條件到期未達成要約期已延長

港股生物醫藥概念股走高，藥明合聯漲近7%，榮昌生物升逾5%

老虎资讯综合

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02268/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02268","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","market":"HK","secType":"STK","nameCN":"藥明合聯","latestPrice":57.1,"timestamp":1774497900002,"preClose":57.1,"halted":0,"volume":2662500,"delay":0,"changeRate":0,"floatShares":1258000000,"shares":1258000000,"eps":1.2681406682278065,"marketStatus":"午間休市","change":0,"latestTime":"03-26 12:05:00","open":57.8,"high":58.5,"low":56.6,"amount":153324783,"amplitude":0.033275,"askPrice":57.2,"askSize":2500,"bidPrice":57.05,"bidSize":9000,"shortable":3,"etf":0,"ttmEps":1.266257704107961,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774501200000},"marketStatusCode":3,"adr":0,"listingDate":1700150400000,"exchange":"SEHK","adjPreClose":57.1,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"volumeRatio":0.969686,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02268\",,,,,undefined,":{"symbol":"02268","floatShares":1258000000,"roa":"8.60%","roe":"17.05%","lyrEps":1.26818,"volumeRatio":0.969686,"shares":1258000000,"dividePrice":0,"high":58.5,"amplitude":0.033275,"preClose":57.1,"low":56.6,"week52Low":24.7,"pbRate":"5.91","psRate":"10.67","week52High":85.5,"institutionHeld":0,"latestPrice":57.1,"committee":0.565217,"eps":1.2681803304689818,"divideRate":0,"volume":2662500,"delay":0,"ttmEps":1.2662973074577382,"open":57.8,"prevYearClose":60.75,"prevWeekClose":52.95,"prevMonthClose":63.15,"prevQuarterClose":60.75,"fiveDayClose":54.2,"twentyDayClose":58.35,"sixtyDayClose":63.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02268\",params:#limit:5,,,undefined,":[{"date":"2026-04-29","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777426200000,"name":null,"time":"","dateTimestamp":1777392000000,"actualEps":null},{"date":"2026-03-23","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774229400000,"name":null,"time":"","dateTimestamp":1774195200000,"actualEps":null},{"date":"2025-08-18","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755480600000,"name":null,"time":"","dateTimestamp":1755446400000,"actualEps":null},{"date":"2025-03-24","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-20","symbol":"02268","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724117400000,"name":null,"time":"","dateTimestamp":1724083200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02268\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02268\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":20,"updateTime":1770393600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02268\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02268","date":"2026-03-25","current":45.093506,"percent":0.148532,"low":30.568632,"twenty":44.877487,"median":58.288916,"eighty":71.661847,"high":153.052589,"avg":63.894504,"sd":26.158789,"marketCap":71831383455},"quantilePoints":[{"date":"2023-11-17","current":130.035431,"twenty":0.435785,"median":0.444801,"eighty":2.787891,"marketCap":32996488000},{"date":"2023-11-24","current":133.579843,"twenty":0.435785,"median":0.444801,"eighty":2.810425,"marketCap":34174934000},{"date":"2023-12-01","current":147.707211,"twenty":0.435785,"median":0.444801,"eighty":2.852893,"marketCap":37945961200},{"date":"2023-12-08","current":132.646927,"twenty":0.435785,"median":0.444801,"eighty":2.935117,"marketCap":33939244800},{"date":"2023-12-15","current":138.75437,"twenty":0.435785,"median":0.444801,"eighty":3.039251,"marketCap":35706913800},{"date":"2023-12-22","current":153.052589,"twenty":0.435785,"median":0.444801,"eighty":3.172504,"marketCap":39360096400},{"date":"2023-12-29","current":145.85951,"twenty":0.435785,"median":0.444801,"eighty":3.326638,"marketCap":37710272000},{"date":"2024-01-05","current":142.305018,"twenty":0.435785,"median":0.444801,"eighty":3.599996,"marketCap":36531826000},{"date":"2024-01-12","current":138.558869,"twenty":0.435785,"median":0.444801,"eighty":3.622774,"marketCap":35589069200},{"date":"2024-01-19","current":141.046625,"twenty":0.435785,"median":0.444801,"eighty":3.635946,"marketCap":36178292200},{"date":"2024-01-26","current":116.23004,"twenty":0.435785,"median":0.444801,"eighty":3.642902,"marketCap":29696839200},{"date":"2024-02-02","current":82.111439,"twenty":0.435785,"median":0.444801,"eighty":3.654128,"marketCap":20952769880},{"date":"2024-02-09","current":67.278987,"twenty":0.435825,"median":0.445043,"eighty":3.68657,"marketCap":17252449440},{"date":"2024-02-16","current":66.713097,"twenty":0.435798,"median":0.44487,"eighty":3.704054,"marketCap":17111035920},{"date":"2024-02-23","current":82.124312,"twenty":0.435798,"median":0.44487,"eighty":3.728385,"marketCap":20952769880},{"date":"2024-03-01","current":86.135235,"twenty":0.435812,"median":0.444939,"eighty":3.767614,"marketCap":21989802360},{"date":"2024-03-08","current":96.662972,"twenty":0.435812,"median":0.444939,"eighty":3.804363,"marketCap":24688443700},{"date":"2024-03-15","current":72.134287,"twenty":0.435812,"median":0.444939,"eighty":3.87411,"marketCap":18407326520},{"date":"2024-03-22","current":82.739174,"twenty":0.435812,"median":0.444939,"eighty":3.907844,"marketCap":21094183400},{"date":"2024-03-28","current":70.236298,"twenty":0.435812,"median":0.444939,"eighty":3.924107,"marketCap":21565561800},{"date":"2024-04-05","current":69.514463,"twenty":0.435772,"median":0.444721,"eighty":3.932321,"marketCap":21329872600},{"date":"2024-04-12","current":72.929575,"twenty":0.435785,"median":0.444801,"eighty":3.970214,"marketCap":22390474000},{"date":"2024-04-19","current":66.691535,"twenty":0.435785,"median":0.444801,"eighty":4.01279,"marketCap":20457822560},{"date":"2024-04-26","current":78.851628,"twenty":0.435812,"median":0.444939,"eighty":62.837086,"marketCap":24158143000},{"date":"2024-05-03","current":79.483533,"twenty":0.435812,"median":0.444939,"eighty":66.70016,"marketCap":24334909900},{"date":"2024-05-10","current":73.189732,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":22461180760},{"date":"2024-05-17","current":65.221538,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19986444160},{"date":"2024-05-24","current":58.278715,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17818103520},{"date":"2024-05-31","current":59.948577,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":18347300940},{"date":"2024-06-07","current":58.299117,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":17820354960},{"date":"2024-06-14","current":64.156468,"twenty":0.435812,"median":0.444939,"eighty":68.608876,"marketCap":19592809620},{"date":"2024-06-21","current":70.500097,"twenty":0.435812,"median":0.444939,"eighty":69.593748,"marketCap":21485024730},{"date":"2024-06-28","current":68.013259,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":20718557850},{"date":"2024-07-05","current":61.893714,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":18850294830},{"date":"2024-07-12","current":63.530585,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":19377240810},{"date":"2024-07-19","current":56.933019,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17365265250},{"date":"2024-07-26","current":56.800526,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":17389217340},{"date":"2024-08-02","current":69.358964,"twenty":0.435812,"median":0.444939,"eighty":70.441134,"marketCap":21221551740},{"date":"2024-08-09","current":72.710245,"twenty":0.435812,"median":0.444939,"eighty":70.597189,"marketCap":22395204150},{"date":"2024-08-16","current":74.003491,"twenty":0.435812,"median":0.444939,"eighty":70.930659,"marketCap":22802389680},{"date":"2024-08-23","current":35.050376,"twenty":0.435812,"median":0.44524,"eighty":71.736965,"marketCap":22742129354},{"date":"2024-08-30","current":36.779427,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":24024219892},{"date":"2024-09-06","current":36.193339,"twenty":0.435812,"median":0.445278,"eighty":71.736965,"marketCap":23652773101},{"date":"2024-09-13","current":36.950123,"twenty":0.435812,"median":0.445611,"eighty":71.736965,"marketCap":24084130665},{"date":"2024-09-20","current":36.912594,"twenty":0.435798,"median":0.445732,"eighty":71.812082,"marketCap":24203952211},{"date":"2024-09-27","current":41.596291,"twenty":0.435798,"median":0.446064,"eighty":71.812082,"marketCap":27439133942},{"date":"2024-10-04","current":49.267448,"twenty":0.435798,"median":0.446181,"eighty":71.812082,"marketCap":32351817312},{"date":"2024-10-10","current":43.61955,"twenty":0.435812,"median":0.446472,"eighty":71.736965,"marketCap":28457617080},{"date":"2024-10-18","current":43.201999,"twenty":0.435798,"median":0.446694,"eighty":71.812082,"marketCap":28038241670},{"date":"2024-10-25","current":43.020102,"twenty":0.435798,"median":0.446852,"eighty":71.812082,"marketCap":27918420124},{"date":"2024-11-01","current":41.699543,"twenty":0.435798,"median":0.446999,"eighty":71.812082,"marketCap":27079669305},{"date":"2024-11-08","current":47.130705,"twenty":0.435852,"median":0.447279,"eighty":71.812082,"marketCap":30374761809},{"date":"2024-11-15","current":46.740281,"twenty":0.435852,"median":0.44753,"eighty":71.812082,"marketCap":29895475627},{"date":"2024-11-22","current":46.01742,"twenty":0.435852,"median":0.447785,"eighty":71.812082,"marketCap":29416189444},{"date":"2024-11-29","current":51.670123,"twenty":0.435852,"median":0.448371,"eighty":71.812082,"marketCap":33010835812},{"date":"2024-12-06","current":54.048034,"twenty":0.435852,"median":0.449445,"eighty":71.812082,"marketCap":34448694360},{"date":"2024-12-13","current":58.707371,"twenty":0.435852,"median":0.45138,"eighty":71.812082,"marketCap":37384322227},{"date":"2024-12-20","current":60.54506,"twenty":0.435852,"median":35.016583,"eighty":71.812082,"marketCap":38342894592},{"date":"2024-12-27","current":58.22519,"twenty":0.435852,"median":35.863906,"eighty":71.812082,"marketCap":36845125272},{"date":"2025-01-03","current":57.033249,"twenty":0.435852,"median":36.241161,"eighty":71.812082,"marketCap":36126195998},{"date":"2025-01-10","current":62.66188,"twenty":0.435852,"median":36.730689,"eighty":71.812082,"marketCap":39541110048},{"date":"2025-01-17","current":54.642634,"twenty":0.436361,"median":37.212991,"eighty":71.812082,"marketCap":34508605132},{"date":"2025-01-24","current":54.868028,"twenty":0.436606,"median":39.470644,"eighty":71.812082,"marketCap":34868069769},{"date":"2025-01-28","current":52.331181,"twenty":0.436643,"median":41.238065,"eighty":71.736965,"marketCap":33430211222},{"date":"2025-02-07","current":57.910706,"twenty":0.437089,"median":42.380717,"eighty":71.8872,"marketCap":36785214499},{"date":"2025-02-14","current":56.82028,"twenty":0.437089,"median":43.020102,"eighty":71.8872,"marketCap":36006374452},{"date":"2025-02-21","current":70.802488,"twenty":0.437089,"median":44.139364,"eighty":71.8872,"marketCap":45112811918},{"date":"2025-02-28","current":60.65941,"twenty":0.437089,"median":45.078416,"eighty":71.8872,"marketCap":38522626910},{"date":"2025-03-07","current":67.088057,"twenty":0.437583,"median":46.607669,"eighty":71.962317,"marketCap":42776291779},{"date":"2025-03-14","current":72.98104,"twenty":0.438098,"median":47.703312,"eighty":71.990989,"marketCap":46550670465},{"date":"2025-03-21","current":80.244903,"twenty":0.438098,"median":49.592986,"eighty":72.978175,"marketCap":51163799971},{"date":"2025-03-28","current":47.906694,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":54840613248},{"date":"2025-04-03","current":43.121995,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":49380552191},{"date":"2025-04-11","current":35.581021,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":40380451549},{"date":"2025-04-17","current":33.597127,"twenty":0.4381,"median":49.700845,"eighty":72.980467,"marketCap":38220427395},{"date":"2025-04-25","current":39.226609,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44663120338},{"date":"2025-05-02","current":40.829264,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":46586700218},{"date":"2025-05-09","current":38.818219,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44603008467},{"date":"2025-05-16","current":39.608151,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":45882474676},{"date":"2025-05-23","current":38.196121,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":44379117053},{"date":"2025-05-30","current":41.172242,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48047309655},{"date":"2025-06-06","current":42.866418,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":50152010328},{"date":"2025-06-13","current":46.041552,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":53888090995},{"date":"2025-06-20","current":41.240748,"twenty":0.437995,"median":49.941945,"eighty":73.022778,"marketCap":48174509918},{"date":"2025-06-27","current":40.971553,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":47994081042},{"date":"2025-07-04","current":46.000985,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":53888090995},{"date":"2025-07-11","current":47.288014,"twenty":0.438098,"median":49.821395,"eighty":72.98104,"marketCap":55339986740},{"date":"2025-07-18","current":50.925924,"twenty":0.438098,"median":50.569275,"eighty":72.98104,"marketCap":59550637905},{"date":"2025-07-25","current":57.660678,"twenty":0.438098,"median":51.683826,"eighty":72.98104,"marketCap":67671179437},{"date":"2025-08-01","current":57.245588,"twenty":0.438098,"median":52.545804,"eighty":72.98104,"marketCap":66768897045},{"date":"2025-08-08","current":57.73965,"twenty":0.43811,"median":53.257543,"eighty":72.98104,"marketCap":67513611340},{"date":"2025-08-15","current":64.222783,"twenty":31.309336,"median":54.856958,"eighty":72.98104,"marketCap":74981664691},{"date":"2025-08-22","current":48.130228,"twenty":34.419063,"median":54.952855,"eighty":72.98104,"marketCap":69501077151},{"date":"2025-08-29","current":46.988345,"twenty":35.581021,"median":54.952855,"eighty":72.98104,"marketCap":68176099944},{"date":"2025-09-05","current":54.370406,"twenty":36.186031,"median":55.113399,"eighty":72.98104,"marketCap":78808670381},{"date":"2025-09-12","current":57.034752,"twenty":36.596757,"median":55.50873,"eighty":72.98104,"marketCap":82819396110},{"date":"2025-09-19","current":59.571504,"twenty":36.911418,"median":56.000464,"eighty":72.98104,"marketCap":86441593568},{"date":"2025-09-26","current":63.204858,"twenty":37.279949,"median":56.495601,"eighty":72.98104,"marketCap":91475834102},{"date":"2025-10-03","current":72.025865,"twenty":37.670679,"median":56.699916,"eighty":72.980467,"marketCap":104491187679},{"date":"2025-10-10","current":60.90024,"twenty":38.189538,"median":56.97042,"eighty":72.98104,"marketCap":88221995708},{"date":"2025-10-17","current":57.936353,"twenty":38.732076,"median":57.121577,"eighty":72.98104,"marketCap":83863080123},{"date":"2025-10-24","current":59.821834,"twenty":39.226609,"median":57.526112,"eighty":72.98104,"marketCap":86623810506},{"date":"2025-10-31","current":63.630196,"twenty":39.774995,"median":57.92353,"eighty":72.98104,"marketCap":92275860553},{"date":"2025-11-07","current":58.827143,"twenty":40.354886,"median":58.251953,"eighty":72.98104,"marketCap":85257233036},{"date":"2025-11-14","current":59.953959,"twenty":41.172242,"median":58.455089,"eighty":72.98104,"marketCap":87136525462},{"date":"2025-11-21","current":57.356344,"twenty":41.596291,"median":58.554061,"eighty":72.98104,"marketCap":83322340564},{"date":"2025-11-28","current":56.291024,"twenty":42.018405,"median":58.564991,"eighty":72.98104,"marketCap":82071768197},{"date":"2025-12-05","current":57.95451,"twenty":42.42494,"median":58.564991,"eighty":72.98104,"marketCap":84642388897},{"date":"2025-12-12","current":56.819112,"twenty":42.866418,"median":58.860686,"eighty":72.98104,"marketCap":83137635317},{"date":"2025-12-19","current":59.902097,"twenty":43.024716,"median":58.930609,"eighty":72.98104,"marketCap":87855221510},{"date":"2025-12-24","current":53.787136,"twenty":43.211711,"median":58.930609,"eighty":72.98104,"marketCap":79132453088},{"date":"2026-01-02","current":52.131715,"twenty":43.875774,"median":58.940897,"eighty":73.022778,"marketCap":76998826280},{"date":"2026-01-09","current":60.097118,"twenty":44.079539,"median":58.920321,"eighty":72.979321,"marketCap":88984788643},{"date":"2026-01-16","current":59.868148,"twenty":44.329264,"median":59.011667,"eighty":72.978748,"marketCap":88933823858},{"date":"2026-01-23","current":58.064858,"twenty":44.542103,"median":59.011667,"eighty":72.978748,"marketCap":86172293688},{"date":"2026-01-30","current":52.991062,"twenty":44.673253,"median":58.945496,"eighty":72.939295,"marketCap":79001941874},{"date":"2026-02-06","current":53.067413,"twenty":44.72485,"median":58.907275,"eighty":72.769063,"marketCap":79316440050},{"date":"2026-02-13","current":54.647287,"twenty":44.764796,"median":58.707371,"eighty":72.713983,"marketCap":82146923636},{"date":"2026-02-20","current":54.893728,"twenty":44.79956,"median":58.576126,"eighty":72.595053,"marketCap":82398522177},{"date":"2026-02-27","current":52.350133,"twenty":44.938454,"median":58.531174,"eighty":72.112603,"marketCap":79442239320},{"date":"2026-03-06","current":49.767005,"twenty":45.116803,"median":58.469542,"eighty":72.01889,"marketCap":74913465582},{"date":"2026-03-13","current":45.00506,"twenty":45.116803,"median":58.377121,"eighty":71.985255,"marketCap":68057405340},{"date":"2026-03-20","current":44.215816,"twenty":45.114658,"median":58.350601,"eighty":71.8872,"marketCap":66610713729},{"date":"2026-03-25","current":42.832163,"twenty":44.877487,"median":58.288916,"eighty":71.661847,"marketCap":71831383455}],"updateTime":1774497967627},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02268\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622041039","title":"【券商聚焦】交銀國際維持藥明合聯(02268)買入評級 指其今年有望迎來M端生產項目的大爆發","url":"https://stock-news.laohu8.com/highlight/detail?id=2622041039","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622041039?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 13:20","pubTimestamp":1774416034,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际研报指，药明合联 2025年收入和经调整净利润分别同比增长46.7%/69.9%，符合此前业绩预告。毛利率大幅提升5.4ppts至36.0%，营业费用率大致平稳。展望2026年，公司预计考虑东曜并表后的收入增速将超40%；毛利率将保持稳定或仅有小幅波动。2026年，公司有望迎来M端生产项目的大爆发，预计2026-28年将合计有30个BLA递交，成为业绩新增长极。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977195","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02268"],"gpt_icon":0},{"id":"2622904986","title":"《大行》里昂：藥明合聯(02268.HK)提高盈利可見性 目標價升至80.9元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622904986","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622904986?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 11:50","pubTimestamp":1774410600,"startTime":"0","endTime":"0","summary":"该行认为这增强公司的盈利可见性，并缓解投资者对增长放缓的担忧。该行料药明合联今年至2028年收入增长分别为38%、31%及28%，纯利预测上调6%至13%，并将其目标价由70.7元上调至80.9元，重申“跑赢大市”评级。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104104222_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512230/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512230/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2622204533","title":"《大行》高盛微降藥明合聯(02268.HK)目標價至85.9元 今年指引符合預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2622204533","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622204533?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:32","pubTimestamp":1774405920,"startTime":"0","endTime":"0","summary":"高盛发表研究报告指，药明合联去年下半年业绩大致符合早前盈喜公告，收入按年升35.9%，净利润升26.4%至7.35亿元人民币(下同)。同期经调整净利润按年增长55%至8.11亿元，经调整净利润率由22%扩大至25%，受惠于营运杠杆及效率提升。该行将药明合联2026至2028年经调整净利润预测分别上调1.8%、上调1.4%及下调0.1%，以反映新加坡厂房投产，惟部分被大部分折旧与摊销成本于2027年入账所抵销；维持对其“买入”评级，目标价由87.1港元微降至85.9港元。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104108628_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104108628_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512184/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512184/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2622504347","title":"中金：維持藥明合聯(02268)跑贏行業評級 目標價88.0港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622504347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622504347?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 10:29","pubTimestamp":1774405754,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到东曜整合和新加坡投产费用上升，维持药明合联27年预测基本不变。维持跑赢行业评级和88.0港元目标价，对应26/27年47.0x/34.5x经调整P/E 。中金主要观点如下：2025年业绩符合该行预期2025年：公司实现营业收入59.44亿元，同比+46.7%;毛利率36%，+5.4ppt;经调整归母净利润15.59亿元，同比+69.9%。苏州基地：公司预计东曜药业收购将于26年3月底完成。2026年资本开支预计约31亿元，2026-2030年总投资约80亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418512.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268"],"gpt_icon":0},{"id":"2621550170","title":"從「賦能者」到「定義者」，CRDMO行業龍頭藥明合聯(02268)的持續進化與價值躍遷","url":"https://stock-news.laohu8.com/highlight/detail?id=2621550170","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621550170?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 14:27","pubTimestamp":1774333622,"startTime":"0","endTime":"0","summary":"一份亮眼的年度答卷，将全球生物偶联药CRDMO龙头药明合联推至聚光灯下。近日，药明合联与Earendil Labs达成潜在交易总额高达8.85亿美元的WuXiTecan-2技术授权合作。Part 2 项目漏斗的质量革命：从“赢得分子”到“锁定未来”财报显示，药明合联累计服务超1000个发现阶段项目，252个进入iCMC开发阶段，2025年有69个项目成功转化。根据财报显示，药明合联海外收入占比已达85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","02268","BK1141","SG9999014674.SGD"],"gpt_icon":0},{"id":"2621119032","title":"《大行》大摩予藥明合聯(02268.HK)評級「增持」 目標價86元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621119032","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621119032?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:55","pubTimestamp":1774320900,"startTime":"0","endTime":"0","summary":"大摩发表研究报告指，药明合联(02268.HK) 去年收入达59.44亿元人民币(下同)，按年升46.7%，毛利达21.39亿元，按年升72.5%，经调整净利润达15.59亿元，按年升69.9%，均略高于早前公布的盈喜预测。该行提及，药明合联重申2025至2030年收入年均复合增长率指引为30%至35%，高于弗若斯特沙利文对行业预测的25.6%水平。该行予其目标价86港元，评级“增持”。(ca/j)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-23 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231107083824175_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511767/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"2621314220","title":"觸底反彈！華寶基金港股通創新藥ETF、港股通醫療ETF攜手衝高3%！業績超預期，藥明合聯、藥明康德強勢領升","url":"https://stock-news.laohu8.com/highlight/detail?id=2621314220","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621314220?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 10:05","pubTimestamp":1774317900,"startTime":"0","endTime":"0","summary":"3月24日，港股全线反弹，医药板块高弹领涨，创新药产业链急速修复，100%创新药研发标的——港股通创新药ETF、高CXO含量的港股通医疗ETF华宝双双高开，盘中一度涨超3%。昨日两只ETF均创下历史收盘新低。　　个股方面，创新药龙头回暖，港股通创新药ETF权重股康方生物、信达生物、石药集团集体涨超2%。港股通医疗ETF华宝持仓药明系CXO龙头绩后大涨，药明合联涨超8%，药明康德涨超7%。　　消息面，昨日晚间，药明系上市公司披露2025年业绩。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e9a6fe8ab3f76a85df162b075e8b47f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-03-24/doc-inhrzysz3556834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["520880","SG9999014674.SGD","LU2045819591.USD","LU0052750758.USD","603259","LU2242644610.SGD","BK1141","LU0320764599.SGD","LU2125910500.SGD","02268","LU1934453819.USD","LU2488822045.USD","LU2328871848.SGD","BK0216","LU1997245094.SGD","02359","LU2495084118.USD","BK1576","BK1583","LU0708995583.HKD","LU1808992512.USD","LU1997245177.USD","LU1046422090.SGD","LU1979443071.USD","LU1969619763.USD","LU1997244956.HKD","LU0456842615.SGD"],"gpt_icon":0},{"id":"2621034874","title":"《大行》瑞銀下調藥明合聯(02268.HK)目標價至90.4元 產能擴張進度良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2621034874","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621034874?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:59","pubTimestamp":1774317540,"startTime":"0","endTime":"0","summary":"瑞银发表研究报告指，药明合联去年下半年业绩符合其初步数据，收入按年升35.9%至32.4亿元人民币(下同)，股东应占纯利7.35亿元，按年升26.4%。2025全年收入及经调整纯利分别按年升46.7%及69.9%。另外，公司的新加坡厂房将于2026年上半年投产，目前已收到10个后期临床制程方案请求，并已与海外客户签订多个项目。该行微调药明合联盈利预测，轻微上调2026及2027年开支预测，目标价由95.7港元下调至90.4港元，认为估值吸引，维持“买入”评级。沽空资料截至 2026-03-23 16:25。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20231117104105862_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511729/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02268"],"gpt_icon":0},{"id":"1143024702","title":"港股異動 | 創新藥概念股走高，藥明合聯升逾8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1143024702","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143024702?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:42","pubTimestamp":1774316564,"startTime":"0","endTime":"0","summary":"3月24日，港股创新药概念股集体走高，$药明合联(02268)$涨超8%，$药明康德(02359)$涨超6%，$康诺亚-B(02162)$涨超4%，$药明生物(02269)$涨超3%，$石药集团(01093)$涨近3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e9a6fe8ab3f76a85df162b075e8b47f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014674.SGD","LU2488822045.USD","BK1574","BK4585","BK1141","BK1161","02268"],"gpt_icon":0},{"id":"1158899695","title":"異動解讀 | 業績超預期！藥明合聯盤中大漲5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=1158899695","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158899695?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:33","pubTimestamp":1774315994,"startTime":"0","endTime":"0","summary":"药明合联(02268.HK)今日盘中大涨5.22%，表现显著强于大市。消息面上，公司于前一交易日盘后公布了2025年度业绩报告。数据显示，公司全年收益达59.44亿元人民币，按年大幅增长46.7%；录得纯利14.8亿元人民币，同比增长38.4%。这份远超市场预期的亮眼成绩单，是推动股价今日走强的主要动力。强劲的业绩增长反映了公司主营业务良好的发展态势与盈利能力，增强了投资者对其未来发展的信心，从而吸引了资金的积极买入。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02268"],"gpt_icon":0},{"id":"2621052036","title":"【券商聚焦】中信證券：GDF-15阻斷劑有望在未來獲批治療腫瘤惡病質","url":"https://stock-news.laohu8.com/highlight/detail?id=2621052036","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621052036?lang=zh_tw&edition=fundamental","pubTime":"2026-03-24 09:01","pubTimestamp":1774314061,"startTime":"0","endTime":"0","summary":"目前GDF-15阻断剂行业处于临床开发阶段，尚无任何药物获批，多数临床管线处于早期阶段，进度最快的为辉瑞公司和CatalYm公司。鉴于Ponsegromab在II期临床试验中的优异结果以及Ponsegromab的II/III期临床试验设计，该机构认为其有望获批治疗肿瘤恶病质，成为GDF-15阻断剂上市后第一个适应症。后续如果Ponsegromab成功上市以及Visugromab读出积极数据，将催化GDF-15阻断剂市场快速增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK1593","LU0348783233.USD","09688","LU1303224171.USD","BK1574","LU1064131003.USD","BK1515","02228","LU0405327148.USD","LU2289578879.USD","02367","06160","BK1585","BK1191","LU1997245094.SGD","LU2328871848.SGD","BK1161","BK1147","LU1580142542.USD","BK1207","600030","IE00B543WZ88.USD","LU1781817850.SGD","03933","LU0640798160.USD","06030","01530","BK1564","LU1794554557.SGD","01099","SG9999014674.SGD","LU0348735423.USD","LU1655091616.SGD","LU0307460666.USD","02268","LU0405327494.USD","06821","BK0276","BK1141","09926","LU1328615791.USD","HK0000165453.HKD","LU0417516902.SGD","IE00BPRC5H50.USD","01789","LU1255011170.USD","BK0028","02196","LU0348825331.USD"],"gpt_icon":0},{"id":"1139697902","title":"藥明合聯2025年業績表現卓越，鞏固其在生物偶聯藥物CRDMO領域的全球領導地位","url":"https://stock-news.laohu8.com/highlight/detail?id=1139697902","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139697902?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 21:17","pubTimestamp":1774271838,"startTime":"0","endTime":"0","summary":"药明合联在2025年取得了卓越的业绩表现，进一步巩固了其在生物偶联药物合同研究、开发与生产（CRDMO）领域的全球领导地位。公司展现出强劲的增长势头和业务韧性，持续获得全球合作伙伴的广泛认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2488822045.USD","BK1141","02268","SG9999014674.SGD"],"gpt_icon":0},{"id":"2621520705","title":"藥明合聯(02268)2025年業績高增延續，「全球擴張+技術賦能」牢築行業龍頭地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2621520705","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621520705?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:26","pubTimestamp":1774268789,"startTime":"0","endTime":"0","summary":"财务与业务数据亮眼，彰显龙头“确定性”药明合联2025年的财务表现，诠释了其在高速成长赛道中的龙头溢价。在自身有机增长动能充沛之际，药明合联把握战略契机，于2026年初启动对东曜药业的控股收购，这并非简单的规模叠加，而是在“有机扩展+战略并购”双轮驱动下，进一步深化全球领导地位的战略棋局。收购预计在2026年3月底完成，随后进入全面整合阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f8405c8fed8428607b7c9694048343b7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417589.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"药明合联(02268)2025年业绩高增延续，“全球扩张+技术赋能”牢筑行业龙头地位","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02268","LU2488822045.USD","SG9999014674.SGD","BK1141"],"gpt_icon":1},{"id":"2621703218","title":"藥明合聯(02268)2025年收益淨利雙增長 公司擁有人應占經調整純利約15.59億元 按年增長69.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621703218","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621703218?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 20:15","pubTimestamp":1774268148,"startTime":"0","endTime":"0","summary":"药明合联(02268)公布2025年业绩，收益约59.44亿元，同比增长46.7%;毛利约21.39亿元，同比增长72.5%;公司拥有人应占经调整纯利约15.59亿元，同比增长69.9%;纯利同比增长38.4%至14.8亿元。集团未完成订单总量亦由2024年12月31日的9.91亿美元增长50.3%至2025年12月31日的14.89亿美元。","market":"us","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_33.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417577.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU2488822045.USD","BK1141","SG9999014674.SGD","02268"],"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交銀國際：CXO行情持續回暖 料板塊估值倍數合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095723?lang=zh_tw&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","02268","BK1583","09688","BK1617","BK1585","LU0634319403.HKD","LU0417516738.SGD","02196","BK1500","LU0307460666.USD","LU0348767384.USD","LU2488822045.USD","LU2399975544.HKD","BK1593","BK1141","02228","BK1207","LU1115378108.SGD","BK1191","LU0417516571.SGD","02367","LU2476274308.USD","03933","LU1770034418.SGD","03329","01789","IE00B543WZ88.USD","BK1574","BK1161","LU2778985437.USD","BK1588","BK1197","LU0348766576.USD","LU1719994722.HKD","06821","09926","LU1794554557.SGD","01099","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","LU1303224171.USD","LU2328871848.SGD","CXO","06160","01530"],"gpt_icon":0},{"id":"2620205448","title":"港股異動 | 東曜藥業-B(01875)再升逾11% 年內股價已翻倍 藥明合聯收購要約正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620205448","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620205448?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 10:00","pubTimestamp":1773972047,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B再涨超11%，年内股价已实现翻倍，截至发稿，涨9.94%，报5.75港元，成交额2108.74万港元。消息面上，药明合联宣布，药明合联对东曜药业的现金要约收购已取得东曜药业60%股权之有效接纳，股份要约已正式生效。根据香港联交所披露的文件，3月17日，WuXi XDC Cayman Inc.以每股均价4.0港元场外增持东曜药业4.64亿股普通股股份，价值约18.55亿港元。增持后，其最新持股数目为4.64亿股股份，好仓比例由0.00%升至60.00%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"716700f540e2f30ce9084471cdfe18ec","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1416349.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK1574","SG9999014674.SGD","BK1141","BK1161","02268","LU2488822045.USD","BK4585","BK4588","01875"],"gpt_icon":0},{"id":"2620203185","title":"【券商聚焦】中國銀河：「十五五」首次將生物醫藥列為國家新興支柱產業，持續發力研發創新","url":"https://stock-news.laohu8.com/highlight/detail?id=2620203185","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620203185?lang=zh_tw&edition=fundamental","pubTime":"2026-03-20 09:23","pubTimestamp":1773969824,"startTime":"0","endTime":"0","summary":"“十四五”规划重点关注医药创新产品产业化、医药产业化技术攻关、疫苗和短缺药品供应保障、产品质量升级、医药工业绿色低碳等五大工程，成效斐然，中国创新药获批上市数量由2015年的11款提升至2024年的92款，2024年共有22款国产化药和17款国产生物药获批上市，国产创新药占比提升至42%。“十五五”规划提出健全医疗、医保、医药协同发展和治理机制，生物医药产业首次被列为国家“新兴支柱产业”，战略定位进一步提升。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODJmOWY1ZDhkZDY4MmEzZDMyMTcwNTE1ODgyMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1976888","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0307460666.USD","LU0348766576.USD","BK4588","LU2778985437.USD","LU2045819591.USD","02359","161726","XBI","HK0000306701.USD","LU2328871848.SGD","02696","601881","HK0000320223.HKD","LU2476274308.USD","06881","LU0348825331.USD","BK1141","BK1588","HK0000306685.HKD","02268","09995","LU2476274720.SGD","BK4585","LU0561508036.HKD","LU0708995583.HKD","09926","LU0348767384.USD","LU1720050803.USD","LU0417516571.SGD","LU1770034418.SGD","06160","LU0348735423.USD","399441","LU2125910500.SGD","LU2242644610.SGD","SG9999014674.SGD","LU0052750758.USD","BK1147","BK1161","BK1564","LU0196878994.USD","IE00B543WZ88.USD","LU0540923850.HKD","06990","BK4581","LU0588546209.SGD","02162","LU1969619763.USD","BK0276"],"gpt_icon":0},{"id":"2620292008","title":"港股異動 | 東曜藥業-B(01875)升逾9% 藥明合聯已取得公司60%股權有效接納 收購要約正式生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2620292008","media":"智通财经","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620292008?lang=zh_tw&edition=fundamental","pubTime":"2026-03-19 09:57","pubTimestamp":1773885457,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B涨超9%，截至发稿，涨8.02%，报4.85港元，成交额1989.09万港元。消息面上，3月18日，药明合联宣布，公司已成功获得东曜药业60%股权之有效接纳，本次收购要约已正式生效。据药明合联介绍，本次收购要约的最后可接纳截止日期为2026年3月31日下午4时，东曜药业股东将在剩余的时间里决策是否接纳本次要约。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK1141","VXUS","BK1574","LU2488822045.USD","BK4585","SG9999014674.SGD","02268","BK4588"],"gpt_icon":0},{"id":"2620449190","title":"港股異動 | 東曜藥業-B(01875)午後升逾5% 藥明合聯收購條件到期未達成 要約期已延長","url":"https://stock-news.laohu8.com/highlight/detail?id=2620449190","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620449190?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 15:23","pubTimestamp":1773732198,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东曜药业-B(01875)午后涨超5%，截至发稿，涨4.04%，报43.8港元，成交额815.65万港元。消息面上，今年1月，东曜药业获药明合联溢价约99%提现金要约。据悉，本次收购成功的关键在于药明合联能否在截止日期前获得至少60%的东曜药业投票权。药明合联此前已经锁定了持有42.16%股份的五大主要股东的“不可撤销承诺”。3月13日，公司公告称，由于接纳条件于首个截止日期未获达成，要约人把首个截止日期延长至2026年3月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","02268","SG9999014674.SGD","VXUS","BK4588","01875","BK1141","BK4585","LU2488822045.USD"],"gpt_icon":0},{"id":"1150046369","title":"港股生物醫藥概念股走高，藥明合聯漲近7%，榮昌生物升逾5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150046369","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150046369?lang=zh_tw&edition=fundamental","pubTime":"2026-03-17 10:28","pubTimestamp":1773714505,"startTime":"0","endTime":"0","summary":"3月17日，$生物(000504)$医药概念股走高，$药明合联(02268)$涨近7%，$荣昌生物(09995)$涨超5%，$君实生物(01877)$、$诺诚健华(09969)$、$药明康德(02359)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5f115a7e903cc298acc05fac997c6569","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","BK1141","SG9999014674.SGD","BK1583","LU1064131003.USD","BK1161","02268","LU2328871848.SGD","BK4581","LU2488822045.USD","BK1574","09995","LU1064130708.USD","BK4585","LU2148510915.USD","LU1969619763.USD","BK4588"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":1,"totalSize":200,"code":"91000000","status":"200"}]}}